Plain-English translation of NCT07434713 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This trial is watching how eyes respond early on to aflibercept 8mg, an injectable medication that helps treat wet age-related macular degeneration (a disease that damages central vision). Researchers will use special eye imaging scans to carefully measure changes in fluid inside and under the retina during the first two months of treatment, and track whether vision improves. The goal is to understand whether what happens in these early weeks can predict how much treatment you'll need over the first year.
Doctors want to know whether the very early response to this medication — what they see on imaging scans and vision tests in just the first two months — can tell them how often patients will need injections throughout the year. Understanding this could help them personalize treatment plans and know sooner whether the medication is working well for you.
You likely qualify if…
You likely don't qualify if…
You will receive injections of the medication into your eye as part of standard care for wet macular degeneration. Throughout the first two months, you'll have several visits where doctors will take detailed imaging scans of your eye (optical coherence tomography or OCT) and measure your vision using standard eye charts. These scans are painless and help doctors see exactly how the fluid inside your eye is responding to treatment. The study lasts two months for the main observation period, with follow-up to track how you do over the first year.
AI-generated summary from trial data · Jun 3, 2026 · Not medical advice
Switzerland